Oxyphenbutazone

• Catalog No.: DB03585
• CAS Number: 129-20-4
• M. F.: C19H20N2O3
• M. W.: 324.3737

SYNONYMS

• IUPAC name: 4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione
• IUPAC Traditional name: cinophen-N
• Brand Name: Flogistin; Flanaril; Butanora; Oxalid; Optimal; Tanderil; Cinophen-n; Crovaril; Infammil; Oxazolioin; Pirabutina; Portoril; Tandacote; Tandearil; Telidac; Telidal; Butaflogin; Butazonic; Butilene; Etrozolidina; Flogoril; Flogostop; Genal; Idrobutazina; Infamil; Metabolite I; Mysite; Neo-farmadol; Offitril; Oxyphentamin; Tanderal; Tendearil; Visubutina; Aradinum; Artroflog; Butanova; Butapirone; Californit; Deflogin; Flamaril; Flegmostam; Flogal; Floghene; Flogitolo; Flogodin; Flopirina; Frabel; Ipabutona; Iridil; Isobutazina; Isobutil; Neofen; Oxazolidin; Oxazolidin-geigy; Oxi-fenibutol; Oxibutol; Oxybuton; Piraflogin; Poliflogil; Rapostan; Remazin; Reumox; Reunabutal; Rumapax; Tandalgesic; Valioil
• Synonyms: Ossifenbutazone [dcit]; 1-(p-Hydroxyphenyl)-2-phenyl-4-butyl-3,5-pyrazolidinedione; 1-Phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-butylpyrazolidine; 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl; 4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione; 4-Butyl-2-(p-hydroxyphenyl)-1-phenyl-3,5-pyrazolidinedione; Oxifenbutazona [inn-spanish]; P-hydroxyphenylbutazone; 1-p-Hydroxyphenyl-2-phenyl-3,5-dioxo-4-N-butylpyrazolidine; 4-Butyl-1-(p-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione; 4-Butyl-2-(4-hydroxyphenyl)-1-phenyl-3,5-dioxopyrazolidine; Hydroxyphenylbutazon; OPB; Oxifenylbutazon; Oxiphenbutazone; Oxiphenbutazonum; Oxyphenbutazonum [inn-latin]; Oxyphenobutazone; Oxyphenylbutazone; P-oxyphenylbutazone; Usaf Ge-14

DATABASE IDS

• PubChem CID: 4641
• CAS Number: 129-20-4
• PubChem SID: 46507285

PROPERTIES

• Hydrophobicity(logP): 2.72 [HANSCH,C ET AL. (1995)]
• Solubility: 0.06 mg/mL at 30 oC [YALKOWSKY,SH & DANNENFELSER,RM (1992)]

DETAILS

Description (English)

• Drug Groups: experimental; withdrawn
• Description: Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.
• External Links: Wikipedia